Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study
AHSCT was followed by greater prevention of relapses compared with ATZ and OCR, and suppressed more profoundly MRI activity than ATZ, but similarly to OCR, albeit with shorter follow up. The risk of accumulating disability was similar among the treated groups. Studies with larger sample sizes and longer follow up may enable confirmation of these findings or detection of any additional differential effects. ANN NEUROL 2025;98:294-307.
Authors
- Varun Mehra (ORCID: https://orcid.org/0000-0001-6572-0971)
- Ashwini Nandoskar
- Victoria Singh‐Curry
- Paolo Antonio Muraro (ORCID: https://orcid.org/0000-0002-3822-1218)
- Richard Nicholas (ORCID: https://orcid.org/0000-0003-0414-1225)
- Alice Mariottini (ORCID: https://orcid.org/0000-0002-1869-7067)
- Antonio Zito (ORCID: https://orcid.org/0000-0001-8720-1742)
- Eleonora Rigoni (ORCID: https://orcid.org/0000-0001-9669-0234)
- Maria Pia Sormani (ORCID: https://orcid.org/0000-0001-6892-104X)
- Eli Silber (ORCID: https://orcid.org/0000-0002-3972-0780)
- Omar Malik (ORCID: https://orcid.org/0000-0001-5168-6258)
- Antonio Scalfari (ORCID: https://orcid.org/0000-0002-7757-0293)
- Roberto Bergamaschi
- Alessio Signori
- Majid Kazmi
- Ian Gabriel
- Federica Pollidoro
Institutions
- Imperial College Healthcare NHS Trust (GB)
- King's College Hospital NHS Foundation Trust (GB)
- Bupa Cromwell Hospital (GB)
- Ospedale Policlinico San Martino (IT)
- King's College Hospital (GB)
- University of Florence (IT)
- Imperial College London (GB)
- University of Genoa (IT)
Publication Details
- Journal
- Annals of Neurology
- Published
- 2025-04-19
- DOI
- https://doi.org/10.1002/ana.27247
- Citations
- 8
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 11.77